Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9877)

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024

The Board is pleased to announce the audited consolidated annual results of the Group for the year ended 31 December 2024, together with comparative figures for the year ended 31 December 2023 as follows. The consolidated financial statements of the Group for the Reporting Period have been audited by the Group's auditor, Ernst & Young, and have been reviewed by the management of the Company together with the Audit Committee.

FINANCIAL HIGHLIGHTS

	Year ended 31 December		Year-on-year
	2024	2023	change
	RMB'000	*RMB'000*	(%)
Revenue	**–**	–	–
Gross profit	**–**	–	–
Loss before income tax	**(185,829)**	(379,096)	-51.0%
Loss for the year	**(185,829)**	(379,096)	-51.0%
Loss attributable to owners of the parent	**(177,510)**	(371,736)	-52.2%
Loss per Share attributable to ordinary equity holders of the parent			
Basic and diluted	**RMB(0.43)**	RMB(0.89)	-51.7%

BUSINESS HIGHLIGHTS

The Company, with its firm implementation of its international development strategy, has been expanding the application and influence of its transcatheter tricuspid valve replacement ("TTVR") products, LuX-Valve series products, around the globe, which has further consolidated its competitive edges in the industry globally.

Ken-Valve, the Company's transcatheter aortic valve replacement ("TAVR") products, received registration approval from the NMPA and a manufacturing license, for which the Company is actively carrying out a full range of commercialization activities.

1. The influence of TTVR continued to increase domestically and internationally and its global leadership position has been fortified, laying a solid foundation for its global commercialization

- The one-year clinical follow-up results of the TRAVEL II, the multicenter clinical trial study of LuX-Valve Plus, were officially published globally at the 2024 Transcatheter Cardiovascular Therapeutics conference (TCT 2024) in the U.S. The one-year clinical follow-up results of the TRAVEL II demonstrated the outstanding clinical performance of LuX-Valve Plus in the mid- to long-term, with low occurrence of safety events and improved efficacy after entering into a longer clinical observation period, allowing the patients to have a further improvement in cardiac function and enjoy a better quality of life, and demonstrating ongoing clinical benefits.

- The one-year clinical follow-up results for patients with annular dilation in the TRAVEL II, the multicenter clinical trial study of LuX-Valve Plus, were published at the PCR London Valves 2024. The outcomes of the study showed that LuX-Valve Plus maintained similar operating time and success rate in patients with annular dilation, which not only effectively reduced tricuspid regurgitation and significantly improved patients' cardiac function one month after the procedure, but also maintained a remarkably low pacemaker implantation rate at the one-year clinical follow-up. The design and clinical performance of LuX-Valve Plus make it an ideal option for the treatment of patients with annular dilation and provide remarkable efficacy and safety.

- LuX-Valve Plus has completed the one-year follow-up of the registration clinical trial in Mainland China and actively submitted the data in accordance with the registration and approval requirements of the NMPA.

- LuX-Valve Plus has completed all of the subject enrollments for the clinical trial carried out in Europe with the aim of obtaining the CE Certificate. Clinical institutions from multiple countries around the world have actively participated in the clinical trial and LuX-Valve Plus won unanimous acclaim from those participating clinical institutions. LuX-Valve Plus has entered the clinical trial stage, and is actively advancing its clinical trial progress in the U.S.

- LuX-Valve Plus has completed a large number of pre-commercial activities worldwide. In order to meet the substantial and urgent demand from tricuspid regurgitation ("TR") patients around the world, we will continue to promote the application of the product globally, in order to further enhance the product's academic position and influence, and lay a solid foundation for the Company's globalization strategy.

- With regard to the LuX-Valve series products, we have trained more than 50 independent physicians and teaching experts in Mainland China, and expanded our footprint to over 220 hospitals with influence in both academia and the industry, covering more than 30 provinces, municipalities, and autonomous regions in Mainland China. In countries and regions other than Mainland China, we have provided training to over 40 independent physicians and teaching experts and have successfully completed implantation procedures or treatment promotions in nearly 100 influential hospitals, which has further enhanced our global influence.

- The global experiences and study outcomes of treating TR patients with LuX-Valve Plus were shared at EuroPCR 2024, New York Valves 2024, Atrio Ventricular Academy Meeting 2024 (AVAM), 11th Mainz Heart Valves Symposium, Hong Kong Valves 2024, and Hong Kong Asia Pacific Congenital and Structural Heart Intervention Symposium 2024 (APCASH), which have captured great attention and received favorable comments from professionals and potential business partners around the globe. We have also shared clinical experiences and live cases at China Valve (Hangzhou) 2024, Beijing Valves 2024, and PCRCCV 2024, demonstrating the outstanding post-procedural results and wide range of applicability of LuX-Valve Plus.

2. The commercialization of Ken-Valve progressed in full swing, enabling us to capture the exact market opportunities available, and optimize our production costs and operational efficiency to achieve revenue growth

- The registration for circulation of Ken-Valve has recently been approved by the NMPA and the Company is actively preparing for its commercialization. We will continue to expand our sales and marketing team and our distribution network to cover more hospitals and scale up our regional penetration. Ken-Valve is a relatively rare TAVR product for the treatment of aortic regurgitation in the market, and the Company will take advantage of this market opportunity to gain market shares in the possible soonest time.

- Ken-Valve features a multi-size design with advantage on allowing for a larger anchoring area, which is expected to accommodate a broad range of patients with aortic regurgitation (or combined stenosis). The Ken-Valve's integrated positioning anchor design ensures stable anchoring, and the design of sealing skirt is expected to reduce the incidence of paravalvular leakage post-procedure. The design of delivery system is expected to shorten the learning curve for physicians and reduce procedural time, which will contribute to the commercialization of the product.

- Innovative product design and easy operation have supported the promotion of our products and surgical trainings. For Ken-Valve products, we have trained more than 30 independent physicians and teaching experts. In addition, surgical training and promotion have covered more than 100 multidisciplinary team experts and nearly 100 hospitals.

3. The registration of JensClip has been accelerated, so as to obtain product registration and achieve commercialization as soon as possible to further enrich the Company's commercial pipeline

- JensClip has completed full enrollment in confirmatory clinical trials and one-year follow up with outstanding clinical results and is expected to submit an application for registration to NMPA as soon as possible in 2025.

- The JensClip features an innovative self-locking design, which is expected to effectively improve mitral regurgitation and reduce leaflet tension. The valve clip allows for flexible shape adjustments, which is expected to enhance procedural safety and improve intraoperative maneuverability. Furthermore, its one-piece release mechanism is designed to minimize potential misoperation risks associated with staged detachment, effectively reducing device operation time.

4. The Company keeps enhancing its comprehensive strength, empowering the Company to achieve its international strategy

- During the Reporting Period, in order to support the development goal of commercialization of our products globally, the Company have established an international standard management system for production and manufacturing, which has significantly increased our production capacity and production yield. In addition, the Company has also adopted a number of cost saving and consumption control measures to ensure its production efficiency. Meanwhile, the Company have constructed and optimized its global supply chain system, improving the efficient supply of the Company's products in the globe in order to meet the increasing overseas demand.

- During the Reporting Period, with our experience in product registration and understanding of regulatory requirements of the major countries/regions such as China, the United States and Europe, we are able to keep improving our research and development technology and production process to align with the management vision and research and development capabilities in the world, which ensures not only the safety and effectiveness of our products, but also the stability of the mass production quality of our products. Moreover, we have further improved the global layout of our intellectual property rights to strengthen the protection to the Company's intellectual property rights.

- Through academic conferences and events, our products matrix has been widely accepted globally, enabling us to access resources and potential partners for our current and future global commercialization. We are exploring to establish cooperation partnership with foreign partners in different phases, which can accelerate the global application of the Company's products.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the year ended 31 December 2024

	Notes	**2024** ***RMB'000***	2023 *RMB'000*
Other income and gains	*4*	**41,559**	43,828
Research and development expenses		**(142,637)**	(288,151)
Administrative expenses		**(68,183)**	(150,309)
Impairment losses on financial assets, net		**(6,662)**	(534)
Other expenses		**(9,617)**	(58)
Finance costs	*6*	**(289)**	(142)
Share of profit of an associate		**–**	18,952
Loss on disposal of an associate		**–**	(2,682)
LOSS BEFORE TAX	*5*	**(185,829)**	(379,096)
Income tax expenses	*7*	**–**	–
LOSS FOR THE YEAR		**(185,829)**	(379,096)
OTHER COMPREHENSIVE (LOSS)/INCOME			
Other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods:			
Exchange differences on translation of foreign operations		**(2,043)**	8,082
OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE YEAR, NET OF TAX		**(2,043)**	8,082
TOTAL COMPREHENSIVE LOSS FOR THE YEAR		**(187,872)**	(371,014)

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (CONTINUED)

For the year ended 31 December 2024

	Note	**2024**	2023
		RMB'000	*RMB'000*
Loss attributable to:			
Owners of the parent		**(177,510)**	(371,736)
Non-controlling interests		**(8,319)**	(7,360)
		(185,829)	(379,096)
Total comprehensive loss attributable to:			
Owners of the parent		**(179,553)**	(363,654)
Non-controlling interests		**(8,319)**	(7,360)
		(187,872)	(371,014)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	*9*		
Basic and diluted			
– For loss for the year (in RMB per share)		**(0.43)**	(0.89)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION
As at 31 December 2024

	Notes	**31 December 2024** ***RMB'000***	31 December 2023 *RMB'000*
NON-CURRENT ASSETS			
Property, plant and equipment		**165,820**	110,178
Other intangible assets		**4,010**	4,140
Right-of-use assets		**28,422**	28,371
Time deposits		**101,539**	–
Other non-current assets		**41,919**	29,490
Total non-current assets		**341,710**	172,179
CURRENT ASSETS			
Inventories		**35,653**	28,126
Prepayments, other receivables and other assets		**44,211**	32,523
Financial assets at fair value through profit or loss		**–**	166,438
Cash and cash equivalents		**605,991**	927,826
Total current assets		**685,855**	1,154,913
CURRENT LIABILITIES			
Trade payables	*10*	**12,097**	16,332
Other payables and accruals		**34,096**	40,431
Interest-bearing bank and other borrowings		**16,015**	–
Lease liabilities		**1,993**	1,918
Total current liabilities		**64,201**	58,681
NET CURRENT ASSETS		**621,654**	1,096,232
TOTAL ASSETS LESS CURRENT LIABILITIES		**963,364**	1,268,411
NON-CURRENT LIABILITIES			
Lease liabilities		**2,119**	1,411
Interest-bearing bank and other borrowings		**44,292**	40,746
Total non-current liabilities		**46,411**	42,157
Net assets		**916,953**	1,226,254
EQUITY			
Equity attributable to owners of the parent			
Share capital	*11*	**417,167**	417,167
Treasury shares	*11*	**(132,292)**	(5,038)
Reserves		**646,887**	820,744
		931,762	1,232,873
Non-controlling interests		**(14,809)**	(6,619)
Total equity		**916,953**	1,226,254

1. CORPORATE AND GROUP INFORMATION

The Company was established in the People's Republic of China (the "PRC") on 8 November 2011 as a limited liability company. On 23 March 2021, the Company was converted into a joint stock company with limited liability under the Company Law of the PRC. The registered office of the Company is located at No.777 Binhai Forth Road, Hangzhou Bay New District, Ningbo, Zhejiang, the PRC.

The Company was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") on 10 October 2022.

During the year, the Company and its subsidiaries (the "Group") were mainly engaged in the research and development of interventional products for the treatment of structural heart diseases and other related medical products.

2.1 BASIS OF PREPARATION

These financial statements have been prepared in accordance with IFRS Accounting Standards (which include all International Financial Reporting Standards, International Accounting Standards ("IASs") and Interpretations) as issued by the International Accounting Standards Board (the "IASB") and the disclosure requirements of the Hong Kong Companies Ordinance. They have been prepared under the historical cost convention, except for financial assets at fair value through profit or loss which have been measured at fair value. These financial statements are presented in Renminbi ("RMB") and all values are rounded to the nearest thousand except when otherwise indicated.

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The Group has adopted the following revised IFRS Accounting Standards for the first time for the current year's financial statements.

Amendments to IFRS 16	*Lease Liability in a Sale and Leaseback*
Amendments to IAS 1	*Classification of Liabilities as Current or Non-current (the "2020 Amendments")*
Amendments to IAS 1	*Non-current Liabilities with Covenants (the "2022 Amendments")*
Amendments to IAS 7 and IFRS 7	*Supplier Finance Arrangements*

2.3 ISSUED BUT NOT YET EFFECTIVE IFRS ACCOUNTING STANDARDS

The Group has not applied the following new and revised IFRS Accounting Standards, that have been issued but are not yet effective, in these financial statements. The Group intends to apply these new and revised IFRS Accounting Standards, if applicable, when they become effective.

IFRS 18	*Presentation and Disclosure in Financial Statements*[3]
IFRS 19	*Subsidiaries without Public Accountability: Disclosures*[3]
Amendments to IFRS 9 and IFRS 7	*Amendments to the Classification and Measurement of Financial Instruments*[2]
Amendments to IFRS 9 and IFRS 7	*Contracts Referencing Nature-dependent Electricity*[2]
Amendments to IFRS 10 and IAS 28	*Sale or Contribution of Assets between an Investor and its Associate or Joint Venture*[4]
Amendments to IAS 21	*Lack of Exchangeability*[1]
Annual Improvements to IFRS Accounting Standards – Volume 11	Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7[2]

1 Effective for annual periods beginning on or after 1 January 2025
2 Effective for annual periods beginning on or after 1 January 2026
3 Effective for annual/reporting periods beginning on or after 1 January 2027
4 No mandatory effective date yet determined but available for adoption

3. OPERATING SEGMENT INFORMATION

For management purposes, the Group is not organised into business units based on their products and only has one reportable operating segment. Management monitors the operating results of the Group's operating segment as a whole for the purpose of making decisions about resource allocation and performance assessment.

Geographical information

Since nearly all of the Group's non-current assets were located in Mainland China during the reporting period, no further geographical information is presented.

4. OTHER INCOME AND GAINS

An analysis of other income and gains is as follows:

	2024	2023
	RMB'000	*RMB'000*
Other income		
Government grants	**6,719**	17,177
Bank interest income	**11,253**	19,326
Others	**9,840**	1,642
Total other income	**27,812**	38,145
Gains		
Foreign exchange differences, net	**2,906**	3,169
Gain on financial assets at fair value through profit or loss	**10,841**	2,514
Total gains	**13,747**	5,683
Total other income and gains	**41,559**	43,828

5. LOSS BEFORE TAX

The Group's loss before tax is arrived at after charging/(crediting):

	Notes	**2024** ***RMB'000***	2023 *RMB'000*
Depreciation of items of property, plant and equipment		**9,198**	8,783
Depreciation of right-of-use assets		**3,103**	2,789
Amortisation of intangible assets		**543**	488
Research and development expenses		**142,637**	288,151
Government grants	*4*	**(6,719)**	(17,177)
Lease payments not included in the measurement of lease liabilities		**2,033**	1,661
Auditor's remuneration		**1,813**	2,300
Bank interest income	*4*	**(11,253)**	(19,326)
Fair value gains, net:			
Financial assets at fair value through profit or loss	*4*	**(10,841)**	(2,514)
Loss on disposal of items of property, plant and equipment		**86**	11
Loss on disposal of an associate		**–**	2,682
Staff cost (excluding directors' and chief executive's remuneration):			
Wages and salaries		**61,105**	65,967
Pension scheme contributions		**13,290**	16,254
Staff welfare expenses		**1,938**	2,564
Share-based arrangement		**(6,015)**	154,121
Total		**70,318**	238,906
Foreign exchange differences, net	*4*	**(2,906)**	(3,169)
Impairment of property, plant and equipment		**6,694**	–
Impairment of other intangible assets		**12**	–
Impairment of financial assets included in prepayments, other receivables and other assets		**6,662**	534
Write-down of inventories to net realisable value		**4,683**	–

6. FINANCE COSTS

An analysis of finance costs is as follows:

	2024 ***RMB'000***	2023 *RMB'000*
Interest on bank and other loans	**1,507**	411
Interest on lease liabilities	**163**	142
Total interest expense on financial liabilities not at fair value through profit or loss	**1,670**	553
Less: Interest capitalised	**1,381**	411
Total	**289**	142

7. INCOME TAX

The Group's principal applicable tax and tax rate are as follows:

(a) Pursuant to the Corporate Income Tax Law of the PRC (the "CIT Law") and the respective regulations, the applicable tax rate of the Company and its subsidiaries in mainland China is 25% (2023: 25%). No provision for Mainland China income tax was made as the Group's entities in the PRC had no estimated assessable profits during the year.

(b) No provision for Hong Kong income tax was made at a rate of 16.5% (2023: 16.5%) as the Group's entity in Hong Kong had no estimated assessable profits during the year.

(c) No provision for Netherlands income tax was made at a rate of 25.8% (2023: 25.8%) as the Group's entity in the Netherlands had no estimated assessable profits during the year.

(d) No provision for United States income tax was made at a rate of 29.8% as the Group's entity in the United States had no estimated assessable profits during the year.

8. DIVIDENDS

No dividend was paid or declared by the Company during the year (2023: Nil).

9. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic loss per share amount is based on the loss attributable to owners of the parent, and the weighted average number of ordinary shares of 408,947,000 (2023: 417,166,000) in issue during the year.

Under the share-based payment schemes, certain share options were granted to eligible employees. Except for the shares without vesting condition and already vested, the vesting requirements of the remaining shares have not been satisfied. The effect of such shares held for share-based payment schemes has not been taken into account in the calculation of basic loss per share until the related employee incentive platforms were deconsolidated on 23 December 2022. Since 23 December 2022, such shares had been included in the calculation of basic loss per share by weighted average number.

The Group had potential dilutive shares throughout the year related to the shares held for the share compensation plan. Due to the Group's negative financial results during the year, shares held for the share compensation plan have an anti-dilutive effect on the Group's loss per share. Thus, diluted loss per share is equivalent to the basic loss per share.

Since December 2023, the Company started to purchase its shares on the Hong Kong Stock Exchange, as further detailed in note 11. Since then, the weighted average number of such shares considered as treasury shares has been included in the calculation of basic loss per share.

10. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period is as follows:

	2024	2023
	RMB'000	*RMB'000*
Trade payables		
Within 1 year	**9,821**	16,303
Over 1 year	**2,276**	29
Total	**12,097**	16,332

Included in the trade payables were an amount due to related parties of RMB578,000 as at 31 December 2024 (2023: RMB2,711,000), which was repayable within 60 days, representing credit terms similar to those offered by the related party to its major customers.

11. SHARE CAPITAL/TREASURY SHARES

A summary of movements in the Company's share capital is as follows:

	Share Capital Total	**Treasury Shares Total**
	RMB'000	*RMB'000*
Issued and fully paid as at 1 January 2023	417,167	–
Shares repurchased *(a)*	–	(5,038)
As at 31 December 2023	417,167	(5,038)
Issued and fully paid as at 1 January 2024	417,167	(5,038)
Shares repurchased *(a)*	–	(127,254)
As at 31 December 2024	417,167	(132,292)

(a) In December 2023, the Company started to purchase its shares on the Hong Kong Stock Exchange at a total consideration of HKD5,449,000 (equivalent to approximately RMB5,038,000). During the year, the Company continued to purchase its shares on the Hong Kong Stock Exchange at a total consideration of HKD139,379,000 (equivalent to approximately RMB127,254,000). The purchased shares will be used as award shares for the selected participants of a share award scheme.

MANAGEMENT DISCUSSION AND ANALYSIS

1. BUSINESS REVIEW

Overview

We are an international medical device company dedicated to the development of interventional products for the treatment of structural heart diseases. Our Company was established in the PRC in November 2011. Since then we have developed a series of treatment solutions targeting different types of structural heart diseases.

Products and Pipeline

As of the date of this announcement, we have several products in various stages of commercialization and research and development, covering transcatheter tricuspid valve intervention ("TTVR"), transcatheter aortic valve intervention ("TAVR") and transcatheter mitral valve intervention ("TMVR") treatment and many other common fields of treatment on structural heart disease. The current focuses of our business operation are the global promotion of our LuX-Valve series of TTVR and replacement products and the commercialization of our Ken-Valve TAVR and replacement products.

With regard to the LuX-Valve series products, we aim to establish the global technological advantage of this series of products and provide support to any other subsequent key products through a diversified approach, including conducting registration clinical trials and obtaining approvals in multiple countries and regions around the world, continuing our regional expansion for our business development, and establishing international strategic collaborations. With regard to Ken-Valve, for which the approval for registration by the NMPA has been obtained, we have obtained relevant permits for the manufacture and sale of such products, initiated the online registration for such products in multiple provinces, municipalities and autonomous regions, and conducted surgical training and product promotion for the physicians and medical teams in a number of hospitals. The Company is actively promoting its commercialization and expects to achieve commercial implantation in the first half of 2025.

The following diagram summarizes the status of our product candidates under development as of the date of this announcement:

Product Categories	Products	Pre-Clinical	Clinical Stage[Note 1]	Registration	Commercialization[Note 2]
TTVR system	LuX-Valve Plus® ★	NMPA approval: Completed one-year follow up of registration clinical trial			
		CE Marking: Completion of enrollment for registration clinical trial			
		FDA Marking: In the process of enrollment and follow up of EFS clinical study			
	LuX-Valve® ★	Admitted into the Green Path and completed the one-year follow up			
TAVR system	Ken-Valve® ★	NMPA approval			
	KenFlex®	Pre-Clinical Stage			
TMVr system	JensClip®	NMPA approval: Completed the subject enrollments for the confirmatory clinical trial and one-year follow up			
TMVR system	JensRelieve®	NMPA approval: In the process of animal trials			
Biomimetic left atrial appendage occluder system	SimuLock®	NMPA approval: In the process of confirmatory clinical trial			
Technology/ Accessories	JeniGal® Anticalcification Technology	NMPA approval			
	LuX-Valve Plus® Catheter Sheath Products	NMPA approval: Submitted for registration			
	Dry-tissue Technology	Pre-Clinical Stage			
	Polymer Leaflet Technology	Pre-Clinical Stage			

★: *Products with ★ are Core Products.*
Note 1: Entering clinical stage is marked by the completion of first human trial.
Note 2: The point in time of expected commercialization is based on the obtaining of product registration certificate.

Our Products and Product Candidates

Tricuspid Valve Product Candidates

LuX-Valve Plus, our proprietary second-generation TTVR system, is designed for patients with severe tricuspid regurgitation and high surgical risk. LuX-Valve Plus works by functionally replacing the patient's dysfunctional native tricuspid valve with a prosthetic valve implanted through a minimally invasive intervention without the need for conventional open-heart surgery. LuX-Valve Plus is a Class III medical device under the classification criteria of the NMPA. LuX-Valve Plus uses a transvascular delivery system through transjugular approach. We expect the transvascular access path not only to effectively simplify the operation procedure with shorter device procedure time, smaller incisions and less damage to the heart tissue, but also to be used in a wider range of situations such as rare and complex anatomical structures. In addition, the delivery system of LuX-Valve Plus is multi-angle adjustable and steerable, allowing physicians to more conveniently adjust the release position and angle, and thereby further increasing the product's safety profile. We have completed the one year follow-up for registration clinical trial for LuX-Valve Plus. We are currently in the process of actively submitting the data in accordance with the registration and approval requirements of the NMPA.

In July 2024, the results of the six-month clinical follow-up of multicenter clinical trial of LuX-Valve Plus (TRAVEL II) were officially published at New York Valves 2024 and the 18th Oriental Congress of Cardiology together with the World Congress of Cardiology (OCC-WCC 2024). For details, please refer to the announcement of the Company dated 2 July 2024.

In October 2024, the results of the one-year clinical follow-up of multicenter clinical trial study of LuX-Valve Plus were published globally at Transcatheter Cardiovascular Therapeutics conference (TCT) 2024. For details, please refer to the announcement of the Company dated 31 October 2024.

In November 2024, the data for patients with annular dilation from the results of one-year clinical follow-up of multicenter clinical trial study of LuX-Valve Plus were published at PCR London Valves 2024. The design of LuX-Valve Plus makes an ideal option for the treatment of patients with annular dilation and provides remarkable efficacy and safety, contributing to promotion and application of the Company's products at a global scale.

LuX-Valve Plus is undergoing the clinical trial carried out in Europe with the aim of obtaining the CE Certificate. Various clinical institutions from multiple countries in the world actively participated in the clinical trial and LuX-Valve Plus won unanimous acclaim from those participating clinical institutions. In October 2023, LuX-Valve Plus was selected for the Expert Panel Scientific Advice Pilot of the European Medicines Agency, and it is expected that the clinical development and clinical research of Lux-Valve Plus will be guided by the expert panels, which will further accelerate the clinical development and registration progress for CE Certificate in Europe, and to expand the global reach and facilitate the internationalization progress of the product.

LuX-Valve Plus has entered the clinical trial phase in the U.S., with continuous accumulation of U.S.-based clinical experience. It was expected that the enrollment for the early feasibility study (EFS) clinical study would be completed in the second quarter of 2025 and the study would then enter pivotal trial preparation, marking a significant progress made by LuX-Valve Plus in the U.S. clinical trial registration and in overseas applications. In September 2023, LuX-Valve Plus was enrolled in the Total Product Life Cycle Advisory Program ("TAP") pilot of the FDA.

A series of preparation activities for commercialization of LuX-Valve Plus have been completed in several regions of the world. In order to meet the substantial and urgent demand from tricuspid regurgitation patients around the world, we will continue to promote the application of our products in different regions worldwide, so as to further enhance the Company's academic position and influence in the world, and lay a solid foundation for the Company's globalization strategy.

LuX-Valve, our proprietary TTVR system, is designed to treat patients with both severe tricuspid regurgitation and high surgical risk. LuX-Valve works by replacing the function of a patient's dysfunctional native tricuspid valve with a prosthetic valve implanted through a minimally invasive intervention without the need for conventional open-heart surgery. LuX-Valve is a Class III medical device under the classification criteria of the NMPA. LuX-Valve was admitted into the Special Examination for Innovative Medical Devices (the "Green Path") by the NMPA in January 2019. In November 2023, the one-year results of the confirmatory clinical trial of LuX-Valve were reported at the PCR London Valves 2023. We are currently in the process of active communication with NMPA, and expect that an application for registration will be submitted to NMPA for approval in due course.

As of the date of this announcement, over 600 cases of implantation of the LuX-Valve series products have been completed worldwide, with a record of the longest follow-up of over 6 years.

Aortic Valve Product Candidates

Ken-Valve, our proprietary first-generation TAVR system, is designed for the treatment of patients with severe aortic regurgitation or combined with aortic stenosis. The Ken-Valve TAVR system features a multi-size stent platform, designed to severe address aortic regurgitation ("AR") or combined aortic stenosis ("AS"), thereby covering the majority of aortic valve pathologies. The valve employs anti-calcification treated bovine pericardial leaflets in a supra-annular design, achieving an optimal balance between large effective orifice area, long-term durability, and effective anti-thrombogenic properties. The integrated positioning keys are engineered to resolve anatomical challenges, such as annular dilation and the lack of anatomical structures for anchoring in the sinus of Valsalva. These keys engage the native leaflets within the sinus, achieving coaptation alignment while generating radial clamping forces. This mechanism ensures stable anchoring and prevents coronary ostium obstruction caused by prosthetic valve interference. An anti-paravalvular leakage (PVL) skirt integrated into the stent's anchoring zone significantly reduced post-procedural PVL risk. The delivery system incorporates active steerable function with a non-wire-controlled steering mechanism, enabling precise navigation in complex anatomies. This innovation is projected to shorten the operator learning curve and improve procedural efficiency. In January 2025, the registration application for Ken-Valve was approved by the NMPA. The Company has been actively carrying out the commercialization of Ken-Valve.

KenFlex, our proprietary next-generation TAVR system, is used for the treatment of severe aortic regurgitation or combined with aortic stenosis. Major upgrade has been made to valves and delivery systems. The flexible and easy-to-operate self-positioning anchors work with the stent to stably fix the valve, while reducing radial support and the impact on the conductive bundle branch, and lowering the pacemaker implantation rate. The delivery system is large-angle adjustable through vascular access, and the self-positioning anchor is convenient to operate, which is expected to improve the accuracy and stability of valve placement. KenFlex is currently in the pre-clinical stage.

Mitral Valve Product Candidates

JensClip, our proprietary clip-based transcatheter mitral valve repair ("TMVr") system, is designed to treat patients with severe mitral regurgitation. The JensClip system introduces an innovative self-locking design, providing secure leaflet fixation to maintain stable coaptation, thus effectively reduces mitral regurgitation while mitigating leaflet stress. Featuring a rhombic linkage mechanism, the valve clip enables enhanced shape adaptability during transvalvular navigation, facilitating smooth valve crossing. Its bidirectional retrievability significantly improves procedural safety.The device enables both simultaneous bilateral and selective unilateral leaflet capture to enhance procedural adaptability. An integrated detachment mechanism minimizes potential risks associated with multi-step detachment processes, effectively releasing accidental deployment errors and shortening procedural time. The subject enrollment of the feasibility clinical trial of JensClip in China was completed in December 2022. As of the date of this announcement, all of the subject enrollments for the confirmatory clinical trial of JensClip and the one-year follow-up were completed and it is expected to submit an application for registration and approval to NMPA in 2025.

JensRelive, our proprietary TMVR (transfemoral) system, is designed to treat patients with severe mitral regurgitation. It works by replacing the function of a patient's dysfunctional native mitral valve without the need for conventional open-heart surgery. JensRelive consists of a prosthetic mitral valve, a delivery catheter system, and a loading system. Our JensRelive uses a special anchoring design, and such design helps the fixation while preventing displacement. In addition, JensRelive is equipped with retrievable and steerable functions, which are expected to improve the valve positioning accuracy and stability during deployment. As of the date of this announcement, we are in the process of conducting pre-clinical study for JensRelive.

Other Structural Heart Diseases Product Candidates

SimuLock, our product candidate for cardiogenic stroke prevention, is our proprietary bionics left atrial appendage occluder system. The three-dimensional sealing and controllable differential endothelial coating design of this product helps to prevent the thromboembolism of left auricle and lower the risk of fatal bleeding for nonvalvular atrial fibrillation patients who are suitable for anticoagulation treatment or have contraindications to anticoagulation treatment. SimuLock adopts a unique design of bionics anchoring, which helps to reduce safety risks. In addition, SimuLock can be modularly assembled as required to cover extensive patients with atrial fibrillation featuring significant differences in anatomical structure of the left atrial appendage. In the third quarter of 2023, we commenced the feasibility clinical trial. In November 2023, we completed the subject enrollment for the first confirmatory clinical trial and clinical implantation of SimuLock. The product is currently in the process of registration clinical trial.

Platform Technology/Accessories

LuX-Valve Plus catheter sheath products are used in conjunction with LuX-Valve Plus system and is currently in the registration stage.

JeniGal anti-calcification technology is currently applicable to all of the Company's commercial products and product candidates, aiming to effectively improve the anti-calcification function of the leaflets and reduce immunogenicity.

Dry-tissue technology and polymer leaflet technology are independently developed by the Company and can be used in the Company's TAVR, TMVR or TTVR product candidates in the future.

Cautionary Statement as required by Rule 18A.08(3) of the Listing Rules: There is no assurance that we will ultimately develop, market and/or commercialize our Core Products or any other product candidates successfully.

Research and Development

Innovative R&D is crucial to the Company's product mix and development strategy. In 2024, we continued to uphold its development idea of driven by clinical pain points and innovative spirit, and kept putting efforts on its research and development layout in the field of interventional treatment of structural heart disease. We have been promoting product technology innovation and improving R&D efficiency from multiple dimensions, including R&D capability enhancement, university cooperation, communication for clinical needs, and external consultation and assistance. With our experience in product registration and understanding of regulatory requirements of the major countries/regions such as China, the United States and Europe, we are able to keep improving our research and development technology and production process to align with the management vision in the world, which has comprehensively increased the Company's R&D efforts in the field of interventional treatment of cardiovascular and structural heart disease, and established a global innovation platform to further consolidate its leading position in domestic and international markets.

With the completion of the subject enrollments for the clinical trial of Lux-Valve Plus in Europe, the successful registration approval for Ken-Valve in China, and the progress of the follow-up of JensClip's domestic clinical trial, the Company has achieved substantial phased results in its comprehensive and international layout in the field of treatment of structural heart disease. In addition, Lux-Valve Plus has obtained approval for the US IDE-EFS trial, further confirming the safety, effectiveness and innovation of the product, and also injecting a driving force into the R&D progress of the product candidates. The Company, while continuing to achieve R&D results, has effectively optimised the cost structure of its R&D work through process reengineering and internal collaboration. With its refined management in project establishment, review and budget control of R&D projects, the efficiency of its R&D work has been greatly improved. In terms of external cooperation, as the Company's products continued to gain momentum in the global market, it has established an academic exchange platform with elite experts in the field of structural heart disease around the world. With the support of domestic and foreign universities and consulting agencies, we have ensured the smooth development of our products.

The Company has always been committed to solving clinical pain points by developing innovative products, By concentrating its major resources, focusing on the areas that it has competitive edges, strengthening industry-university-research-medical cooperation, the Company is able to ensure that its product pipeline is in a healthy and sustainable leading position, and it can provide more scientific and effective treatments for the patients with structural heart disease.

Intellectual Property

As of the date of this announcement, we had:

- Three Core Products, as well as a number of other product candidates in various stages of development; and

- 197 issued patents and 214 patent applications in more than 19 countries or regions.

Manufacturing

We have full manufacturing capabilities, including production lines for stents, valves, and delivery systems, respectively. We procured equipment and machinery from reputable suppliers and completed comprehensive commissioning and qualification steps to verify that the equipment and programs are installed according to the requisite specifications. The Company has obtained ISO 13485 certification. We believe our manufacturing capability will give us an edge in clinical trials and commercialization.

Our manufacturing facility is located in Ningbo, Zhejiang the PRC, and along with two adjacent properties, occupy approximately 7,000 sq.m.. It is designed and built for manufacturing medical devices in compliance with GMP requirements with full manufacturing capability and ready for commercial-scale production. Our manufacturing facility has several production lines, including production lines for stents, valves, and delivery systems, respectively.

Commercialization

Commercialization of our product candidates is critical to our future growth and success. To drive our product launch and bring our product candidates to market, we are assembling our core commercial leadership team in anticipation of product launch.

As of the date of this announcement, we have built a professional and efficient commercial team responsible for the pre-market introduction and education of the Core Products. The Company's clinical medicine team has set up a professional team with medical literacy and medical operations understanding, which has established the global operating standards through high-standard clinical follow-up feedbacks. At the same time, the sales and marketing team has started preparation for pre-entering the market globally to enhance the Company's market expansion and marketing capabilities to further enhance commercialization capabilities.

The sales and marketing team has started preparation work for product admission as well as the construction of regional distributors' network to enhance the Company's market expansion and marketing capabilities to further enhance commercialization capabilities. As of the date of this announcement, for LuX-Valve series products, we have expanded to more than 220 hospitals in Mainland China with influence in both academia and industry, with presence in more than 30 provinces, municipalities and autonomous regions. We have trained more than 50 independent physicians and teaching experts as of the date of this announcement. We plan to scale up our commercial team to cover the increasing number of hospitals for the upcoming product launch. In countries and regions other than Mainland China, we have provided training to over 40 independent physicians and teaching experts, and have completed implantation procedures or treatment coverage in nearly 100 hospitals. For Ken-Valve, we have trained more than 30 independent physicians and teaching experts. In addition, surgical training and promotion have covered more than 100 multidisciplinary team experts and nearly 100 hospitals.

We have participated in both domestic and overseas high-quality academic conferences in the field of structural heart diseases, including industry conferences, associations, and annual meetings. Such conferences include 2024 Transcatheter Cardiovascular Therapeutics Conference, PCR London Valves 2024, AVAM 2024, Mainz Heart Valve Symposium in Germany, APCASH 2024, Hong Kong Valves, New York Valves 2024, EuroPCR 2024, PCRCCV 2024, 2024 Beijing Valves, OCC-WCC 2024, Taipei Valve Summit 2024, China Valve (Hangzhou) 2024, etc.. These events help us to increase the market visibility of our product candidates, share our clinical results and enhance experts' awareness of clinical benefits of our product candidates. Going forward, we plan to organize and participate in more academic conferences of the aforementioned types globally on a yearly basis.

We are exploring global business development cooperation and partnership with foreign medical device manufacturers and enterprises in different phases, which would accelerate the global commercialization of the Company's products around the world.

Future Development

Our vision is to become a global pioneering medical device enterprise with a comprehensive offering of innovative products for the treatment of structural heart diseases. We plan to implement the following strategies to achieve our goal:

- expedite the application of our Core Products around the world, in order to meet the huge and urgent clinical demands for structural heart diseases treatment;

- specialize in structural heart diseases and build upon our R&D capabilities and seek strategic collaborations to optimize our product portfolio; and

- expand our footprint to become an industry pioneer.

II. FINANCIAL REVIEW

Other Income and Gains

Our other income and gains primarily consist of (i) gains on financial assets at fair value through profit or loss, representing the realized and unrealized gains from wealth management products we purchased; (ii) net foreign exchange gains in connection with bank balance and cash denominated in U.S. dollars; (iii) government grants, primarily including subsidies received from the local governments to support our R&D activities and business operations; (iv) interest income from bank deposits; and (v) others. Our other income and gains decreased from RMB43.8 million in 2023 to RMB41.6 million in 2024. The decrease was primarily attributable to a reduction in government grants and interests from bank deposits, partially offset by gains on financial assets at fair value through profit or loss.

Research and Development Expenses

Our R&D expenses primarily consist of (i) share-based compensation expenses; (ii) staff costs, including salaries, bonus and welfare for R&D personnel; (iii) costs of raw materials and consumables used for R&D of our product candidates; and (iv) third-party contracting costs, primarily including payments to contract research organizations, clinical trial sites, and other medical institutions and testing fees incurred for preclinical studies and clinical trials.

Our R&D expenses decreased from RMB288.2 million in 2023 to RMB142.6 million in 2024. The decrease was primarily attributable to reductions in share-based compensation expenses, staff costs and costs of raw materials.

The following table sets forth a breakdown of our R&D expenses in absolute amounts for the periods indicated:

	Year ended 31 December	
	2024	2023
	RMB'000	*RMB'000*
Share-based compensation expenses	**4,360**	125,073
Staff costs	**48,982**	62,392
Costs of raw materials and consumables used	**10,381**	32,733
Third-party contracting costs	**43,715**	39,713
Depreciation and amortization	**7,424**	6,965
Others	**27,775**	21,275
Total	**142,637**	288,151

Administrative Expenses

Our administrative expenses primarily consist of (i) share-based compensation expenses; (ii) staff costs, including salaries, bonus and welfare for administrative personnel; (iii) professional service fees incurred primarily in relation to recruitment, legal and accounting services; (iv) depreciation and amortization; (v) traveling and transportation expenses; and (vi) others. In 2023 and 2024, we recorded share-based compensation expenses of RMB80.3 million and RMB1.3 million respectively, under our administrative expenses.

Our administrative expenses decreased from RMB150.3 million in 2023 to RMB68.2 million in 2024. The decrease was primarily attributable to reductions in share-based compensation expenses and professional service fees.

The following table sets forth a breakdown of our administrative expenses in absolute amounts for the periods indicated:

	Year ended 31 December	
	2024	2023
	RMB'000	*RMB'000*
Share-based compensation expenses	**1,336**	80,315
Staff costs	**34,025**	29,258
Professional service fees	**10,444**	19,808
Depreciation and amortization	**4,333**	5,095
Traveling and transportation expenses	**3,784**	4,790
Utilities and office expenses	**1,234**	844
Others	**13,027**	10,199
Total	**68,183**	150,309

Other Expenses

Our other expenses mainly consist of: (i) loss on disposals of property, plant and equipment; (ii) impairment of property, plant and equipment; (iii) write-down of inventories and (iv) others.

Our other expenses increased from RMB58,000 in 2023 to RMB9.6 million in 2024. The increase was primarily attributable to the increase in impairment losses on property, plant, and equipment and inventory write-downs.

Impairment Losses on Financial Assets, Net

Our impairment losses on financial assets increased from RMB534,000 in 2023 to RMB6.7 million in 2024. The increase was primarily attributable to the rise in impairments of prepayments, other receivables and other assets.

Finance Costs

Our finance costs mainly consist of lease liabilities and borrowings from Shareholders.

Our finance costs increased from RMB142,000 for the year ended 31 December 2023 to RMB289,000 for the Reporting Period. The increase was primarily attributable to an increase in interest on other borrowings.

Income Tax Expenses

We did not incur any income tax expenses during the Reporting Period.

Loss for the Year

Based on the factors described above, our net losses amounted to RMB379.1 million and RMB185.8 million in 2023 and 2024 respectively.

Working Capital

Our primary uses of cash relate to the R&D of our product candidates and capital expenditures. Our net cash used in operating activities was RMB217.6 million for the year ended 31 December 2024, primarily due to R&D expenses and administrative expenses we incurred during the Reporting Period. Our operating cash flow will continue to be affected by our R&D expenses. During the Reporting Period, we primarily funded our working capital requirements through capital contributions from our Shareholders. We monitor and maintain a level of cash and cash equivalents deemed adequate to finance our operations and mitigate the effects of fluctuations in cash flows. Going forward, we believe our liquidity requirements for conducting our R&D activities and realizing the commercialization of our product candidates, as well as supporting our future expansion plans will be satisfied by using funds from a combination of our cash and bank balances, net proceeds from the Global Offering and other funding sources as we believe appropriate.

Our net cash generated from investing activities was RMB5.6 million for the year ended 31 December 2024, primarily due to the proceeds from disposal of financial assets at fair value through profit or loss partially offset by the purchase of items of property, plant and equipment during the Reporting Period.

Our net cash used in financing activities was RMB110.7 million for the year ended 31 December 2024, primarily due to the purchase of Shares at the Company's instruction in connection with the H Shares Scheme partially offset by the proceeds from new bank and other loans during the Reporting Period.

As of 31 December 2024, we had cash and cash equivalents of RMB606.0 million, representing a decrease of 34.7% compared to RMB927.8 million as at 31 December 2023.

Our net current assets decreased from RMB1,096.2 million as at 31 December 2023 to RMB621.7 million as at 31 December 2024, primarily attributable to the purchase bank time deposits, R&D expenses, and administrative expenses incurred during the Reporting Period.

Capital Expenditure

We regularly incur capital expenditures to expand our operations, upgrade our facilities, enhance our development capabilities and increase our operating efficiency. Our capital expenditures primarily consisted of expenditures on properties, machinery and office equipment. We expect our main sources of funding for capital expenditure in 2025 to be from bank and other borrowings, net proceeds from the Global Offering, and capital contributions from our Shareholders.

Our capital expenditures decreased from RMB78.6 million for the year ended 31 December 2023 to RMB71.7 million for the Reporting Period. The decrease was primarily attributable to the decrease in capital expenditures of property, plant and equipment.

Key Financial Ratios

The following tables sets forth the key financial ratios as at the dates indicated:

	As of 31 December	
	2024	2023
Current ratio[(1)]	**10.7**	19.7
Quick ratio[(2)]	**10.1**	19.2
Gearing ratio[(3)]	**10.8%**	7.6%

Notes:

(1) Current ratio is calculated based on total current assets divided by total current liabilities.

(2) Quick ratio is calculated based on total current assets less inventories divided by total current liabilities.

(3) Gearing ratio is calculated based on total liabilities divided by total assets and multiplied by 100%.

Indebtedness

As of 31 December 2024, we had total bank and other borrowings of RMB60.3 million as compared to RMB40.7 million bank borrowings as of 31 December 2023, of the borrowings, approximately RMB44.3 million are have maturity over one year and RMB16.0 million are due within 1 year.

Our lease liabilities increased from RMB3.3 million as at 31 December 2023 to RMB4.1 million as at 31 December 2024, primarily attributable to new lease agreements entered into by the Group during the Reporting Period.

Pledge of Assets

As at 31 December 2024, certain leasehold land with a carrying amount of RMB24.3 million was pledged to secure the bank borrowings of RMB15.8 million.

Contingent Liabilities

As of 31 December 2024, we did not have any material contingent liabilities.

Significant Investments, Material Acquisitions and Disposals

During the Reporting Period, the Group did not hold any significant investments and we did not conduct any material acquisitions or disposals. Save as disclosed as above, the Group does not have any specific plan on material investments or capital assets as of the date of this announcement.

Foreign Exchange Exposure

During the Reporting Period, we mainly operated in China and a majority of our transactions were settled in RMB, the functional currency of our Company. We are exposed to foreign currency risk mainly arising from exchange rate fluctuations of U.S. dollars against RMB. We currently do not have a foreign currency hedging policy. However, our management monitors foreign exchange exposure and will consider appropriate hedging measures in the future should the need arise.

Material Litigation

The Company was not involved in any material litigation or arbitration during the Reporting Period. The Directors are also not aware of any material litigation or claims that are pending or threatened against the Group as of 31 December 2024.

HUMAN RESOURCES

As of 31 December 2024, the Group has 211 employees (as of 31 December 2023: 376 employees) in total. In compliance with the relevant labor laws, we enter into individual employment contracts with our employees covering matters such as terms, wages, bonuses, employee benefits, workplace safety, confidentiality obligations, non-competition and grounds for termination.

In addition, we are required under the PRC law to make contributions to statutory employee benefit plans (including pension plans, medical insurance and housing funds) at a certain percentage of our employees' salaries, including bonus and allowances, up to a maximum amount specified by the local government.

We recruit our employees based on a number of factors, including work experience, educational background and the requirements of a relevant position. To remain competitive in the labor market, we provide competitive salaries, opportunity to participate in various incentive plans and other benefits to our employees. We invest in continuing education and training programs, including internal and external training, for our management staff and other employees to upgrade their skills and knowledge. We provide our employees with regular feedback as well as internal and external training in various areas, such as product knowledge, project development and team building. We also assess our employees based on their performance to determine their salaries, promotion and career development. We believe our benefits, working environment and development opportunities for our employees have contributed to good employee relations and employee retention.

Our Company has adopted the Employee Incentive Plans on 30 October 2020 and 27 April 2021 (details of which are set forth in the section headed "Employee Incentive Plans" in the 2023 Annual Report of the Company, the Company's circular dated 6 December 2022, and in our Prospectus). The Company has also adopted the H Share Scheme on 15 December 2023 (details of which are set forth in the section headed "The H Share Scheme" in the 2023 Annual Report of the Company and the Company's circular dated 28 November 2023).

USE OF NET PROCEEDS FROM THE GLOBAL OFFERING

On 10 October 2022, the Company was successfully listed on the Stock Exchange. The net proceeds received by the Group from the Global Offering (after deducting underwriting fees and relevant expenses) amounted to HK$206.4 million. The Company will apply such net proceeds in accordance with the business objectives as set out in the Prospectus.

The table below sets out the planned applications of the use of net proceeds (as set out in the Prospectus) from the Global Offering and actual usage as at 31 December 2024:

Use of proceeds	Percentage of total net proceeds	Allocation of net proceeds *(HK$ million)*	Unutilized net proceeds as of 31 December 2023 *(HK$ million)*	Utilized net proceeds during the Reporting Period *(HK$ million)*	Unutilized net proceeds as of 31 December 2024 *(HK$ million)*	Expected timeline for full utilization of unutilized net proceeds
To fund the R&D, manufacturing and commercialization of our Core Products, namely, LuX-Valve and Ken-Valve	65.0%	134.1	125.7	6.0	119.7	by 31 December 2026
To fund the R&D, clinical trials and product registration of other product candidates in our pipeline, including LuX-Valve Plus, KenFlex and mitral valve products	25.0%	51.6	32.9	7.6	25.3	by 31 December 2026
Working capital and general corporate purposes	10.0%	20.7	10. 4	0.5	9.9	by 31 December 2025
Total	100%	206.4	169. 0	14.1	154.9	

The expected timeline for utilizing the net proceeds from the Global Offering is based on the best estimation of future market conditions made by the Company and subject to changes in accordance with our actual business operation.

EVENTS AFTER THE REPORTING PERIOD

There is no material subsequent event undertaken by the Company or by the Group after the Reporting Period and up to the date of this announcement.

FINAL DIVIDEND

The Board did not recommend the payment of a final dividend for the Reporting Period.

GRANT OF REPURCHASE MANDATE AND AMENDMENT OF H SHARE SCHEME

On 27 August 2024, the Board has resolved to propose to approve including, among others (i) the granting of the repurchase mandate of H Shares to the Board; (ii) the amendment of the H Share Scheme; and (iii) the amendments to the internal management policies of the Company. The grant of repurchase mandate to the Board, the amendments of the H Share Scheme and such amendments to the internal management policies were duly approved by the Shareholders at the 2024 first extraordinary general meeting of the Company held on 19 September 2024. For further details, please refer to the circular of the Company dated 27 August 2024 respectively.

ANNUAL GENERAL MEETING

The AGM will be held on Thursday, 22 May 2025. Notice of the AGM and all other relevant documents will be published and despatched to Shareholders in the manner required by the Listing Rules in due course.

CLOSURE OF REGISTER OF MEMBERS

In order to determine the entitlement to attend and vote at the AGM, the register of members of the Company will be closed from Monday, 19 May 2025 to Thursday, 22 May 2025, both days inclusive, during which period no transfer of shares will be registered. All transfer documents of the Company accompanied by the relevant share certificates must be lodged with the Company's H Share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, for registration not later than 4:30 p.m. on Friday, 16 May 2025.

CORPORATE GOVERNANCE PRACTICES

The Group is committed to maintaining high standards of corporate governance to safeguard the interests of the Shareholders and to enhance corporate value and accountability.

The Company has adopted the CG Code contained in Appendix C1 to the Listing Rules as its own code of corporate governance. During the Reporting Period, the Company has complied with all applicable code provisions of the CG Code save and except for the following deviation from code provision C.2.1 of Part 2 of the CG Code.

Under code provision C.2.1 of Part 2 of the CG Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. During the Reporting Period, Mr. LV Shiwen ("Mr. LV") was our chairman of the Board and the chief executive officer of our Company. Although such appointment is not consistent with such code provision C.2.1 during the Reporting Period, our Board considers that with the extensive experience of Mr. LV in the medical devices industry and having served in our Company since January 2013, vesting the roles of chairman and chief executive officer of our Company in the same person during the Reporting Period was beneficial to the management of our Group. On 15 January 2025, Mr. LV has resigned as the chief executive officer of the Company, and that Mr. PAN Fei has been appointed as the chief executive officer of the Company on the same date. Subsequent to the above change, the Company has re-complied with the CG code regarding the separation of role of chairman of the Board and the chief executive officer under the Listing Rules.

The balance of power and authority is ensured by the operation of our Board, our Supervisors and our senior management, which comprises experienced and visionary individuals. Our Board currently comprises an executive Director, five non-executive Directors and three independent non-executive Directors, and therefore has a strong independence element in its composition. The Board will closely monitor to ensure that there is a diverse set of skills and experiences that are relevant to the organisations strategic objectives and that there are no significant gaps in the collective expertise to maintain a Board skills matrix. The Board will also conduct regular evaluation of the Board's performance from time to time and to continue to review the effectiveness of the corporate governance structure of the Group to ensure compliance with the CG Code.

CHANGE OF INFORMATION OF DIRECTOR

On 15 January 2025, Mr. PAN Fei was appointed as the chief executive officer of the Company. For details, please refer to the announcement of the Company dated 15 January 2025. Mr. LV Shiwen was also redesignated as a non-executive Director on the date of this announcement.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code contained in Appendix C3 to the Listing Rules as its own code of conduct regarding securities transactions by the Directors and Supervisors. Having made specific enquiries with all Directors and Supervisors, each of them has confirmed that he/she has complied with the Model Code during the Reporting Period. As required by the Company, relevant officers and employees of the Company are also bound by the Model Code, which prohibits them to deal in securities of the Company at any time when he/she possesses insider information in relation to those securities. No incident of non-compliance of the Model Code by the employees who are likely to be in possession of inside information of the Company was noted by the Company.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

During the Reporting Period, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including sale or transfer of treasury shares (as defined under the Listing Rules)). The Company does not have any treasury shares as defined under Listing Rules as at 31 December 2024.

REVIEW OF ANNUAL RESULTS BY THE AUDIT COMMITTEE

The Board has established the Audit Committee which comprises three independent non-executive Directors, namely Ms. Du Jiliu, Dr. Lin Shoukang and Dr. Mei Lehe. Ms. Du Jiliu serves as the chairperson of the Audit Committee, who has the professional qualifications and experience in financial matters in compliance with the requirements of the Listing Rules. The primary duties of the Audit Committee are to provide an independent view of the Company's financial reporting process, internal control and risk management system, oversee the audit process and perform other duties and responsibilities as assigned by the Board.

The Audit Committee, together with the management and external auditor of the Company, has reviewed the annual results and the accounting principles and policies adopted by the Company and discussed internal control and financial reporting matters (including the review of the consolidated financial statements of the Group for the year ended 31 December 2024) of the Group, and is of the view that the annual results of the Group is prepared in accordance with applicable accounting standards, rules and regulations and appropriate disclosures have been duly made.

SCOPE OF WORK FOR ANNUAL RESULTS ANNOUNCEMENT BY AUDITOR

The financial information set out in this announcement does not constitute the Group's audited accounts for the year ended 31 December 2024, but represents an extract from the consolidated financial statements of the Company for the year ended 31 December 2024 which have been audited by the auditor of the Company, Ernst & Young in accordance with Hong Kong Standards on Auditing issued by the Hong Kong Institute of Certified Public Accountants.

PUBLICATION OF THE ANNUAL RESULTS AND 2024 ANNUAL REPORT

This annual results announcement is published on the websites of the Stock Exchange (https://www.hkexnews.hk) and the Company (https://www.jenscare.com). The annual report of the Company for the year ended 31 December 2024 containing all the information required by the Listing Rules will be dispatched to the Shareholders who requested printed copy and will be published on the respective websites of the Stock Exchange and the Company on or before the end of April.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings.

"AGM"	the 2024 annual general meeting of the Company to be held on Thursday, 22 May 2025
"Audit Committee"	the audit committee of the Board
"Board of Directors" or "Board"	the board of Directors
"CE Certificate"	Conformité Européenne, an administrative marking that indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area (EEA)
"CG Code"	the "Corporate Governance Code" as contained in Appendix C1 to the Listing Rules
"China" or "PRC"	the People's Republic of China, which, for the purpose of this announcement and for geographical reference only, excludes Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan, the PRC
"Company" or "our Company"	Jenscare Scientific Co., Ltd. (宁波健世科技股份有限公司), a joint stock company incorporated in the PRC with limited liability on 23 March 2021, or, where the context requires (as the case may be), its predecessor Ningbo Jenscare Biotechnology Co., Ltd. (宁波健世生物科技有限公司), a limited liability company established in the PRC on 8 November 2011
"Core Product(s)"	LuX-Valve, LuX-Valve Plus and Ken-Valve, the designated "core products" as defined under Chapter 18A of the Listing Rules
"Domestic Share(s)"	ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for and paid up in RMB and are unlisted Shares which are currently not listed or traded in any stock exchange
"Global Offering"	the global offering of the H Shares, details of which are set forth in the Prospectus

"Group", "our Group", "our", "we", or "us"	the Company and all of its subsidiaries, or any one of them as the context may require or, where the context refers to any time prior to its incorporation, the business which its predecessors or the predecessors of its present subsidiaries, or any one of them as the context may require, were or was engaged in and which were subsequently assumed by it
"H Shares"	overseas listed foreign invested ordinary share(s) in the ordinary share capital of our Company, with a nominal value of RMB1.00 each, which are to be subscribed for and traded in Hong Kong dollars and which are listed on the Stock Exchange
"H Share Scheme"	the H Share award scheme approved and adopted by the Shareholders at the extraordinary general meeting of the Company held on 15 December 2023
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Hong Kong dollars", "HK dollars" or "HK$"	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
"IFRS"	International Financial Reporting Standards, as issued from time to time by the International Accounting Standards Board
"Listing Rules"	the Rules Governing the Listing of Securities on Stock Exchange (as amended, supplemented or otherwise modified from time to time)
"Model Code"	the "Model Code for Securities Transactions by Directors of Listed Issuers" set out in Appendix C3 to the Listing Rules
"NMPA"	the National Medical Product Administration of the PRC (中國國家藥品監督管理局), successor to the China Food and Drug Administration or CFDA (國家食品藥品監督管理總局)
"Prospectus"	the prospectus of the Company dated 23 September 2022
"Reporting Period"	the year ended 31 December 2024
"R&D"	research and development
"RMB"	Renminbi, the lawful currency of the PRC
"Share(s)"	ordinary share(s) in the capital of our Company with a nominal value of RMB1.00 each, comprising Unlisted Shares and H Shares

"Shareholder(s)"	holder(s) of the Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"United States" or "U.S."	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
"Unlisted Foreign Share(s)"	ordinary share(s) issued by the Company, with a nominal value of RMB1.00 each, which are subscribed for and paid for in currency other than RMB by foreign investors and are not listed on the Stock Exchange
"Unlisted Share(s)"	Domestic Shares and Unlisted Foreign Shares
%	per cent

By order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei
Executive Director and CEO

Hong Kong, 21 March 2025

As at the date of this announcement, the board of Directors comprises Mr. PAN Fei, as executive Director; Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing, as non-executive Directors; and Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe, as independent non-executive Directors.